thalidomide has been researched along with Enlarged Spleen in 12 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a patient with very advanced myelofibrosis and huge splenomegaly who showed a complete hematological response to low dose thalidomide with reversal of splenomegaly and bone narrow fibrosis after 30 months of the treatment." | 5.34 | Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly. ( Berrebi, A; Feldberg, E; Shvidel, L; Spivak, I, 2007) |
| " We conducted a phase II, multicentre, study to investigate thalidomide in severely symptomatic indolent and aggressive systemic mastocytosis." | 5.17 | Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. ( Barete, S; Bruneau, J; Canioni, D; Chaby, G; Chandesris, O; Damaj, G; Diouf, M; Dubreuil, P; Durieu, I; Grosbois, B; Gruson, B; Hermine, O; Lanternier, F; Larroche, C; Livideanu, C; Lortholary, O; Marolleau, JP; Sevestre, H, 2013) |
| "Thalidomide was administered together with current therapy to 63 patients, starting at 50 mg daily and increasing to 400 mg as tolerated." | 2.71 | Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. ( Balestri, F; Barosi, G; Barulli, S; Bauduer, F; Bendotti, C; Bordessoule, D; Broccia, G; Buccisano, F; Caenazzo, A; Demory, JL; Dupriez, B; Falcone, A; Gentili, S; Grossi, A; Ilariucci, F; Le Bousse-Kerdiles, MC; Marchetti, M; Pecci, A; Viarengo, G; Volpe, A, 2004) |
| "Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration." | 2.53 | [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. ( Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S, 2016) |
| "We report a patient with very advanced myelofibrosis and huge splenomegaly who showed a complete hematological response to low dose thalidomide with reversal of splenomegaly and bone narrow fibrosis after 30 months of the treatment." | 1.34 | Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly. ( Berrebi, A; Feldberg, E; Shvidel, L; Spivak, I, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gau, YC | 1 |
| Hsiao, HH | 1 |
| Liu, YC | 1 |
| Yeh, TJ | 1 |
| Gruson, B | 1 |
| Lortholary, O | 1 |
| Canioni, D | 1 |
| Chandesris, O | 1 |
| Lanternier, F | 1 |
| Bruneau, J | 1 |
| Grosbois, B | 1 |
| Livideanu, C | 1 |
| Larroche, C | 1 |
| Durieu, I | 1 |
| Barete, S | 1 |
| Sevestre, H | 1 |
| Diouf, M | 1 |
| Chaby, G | 1 |
| Marolleau, JP | 1 |
| Dubreuil, P | 1 |
| Hermine, O | 1 |
| Damaj, G | 1 |
| Cervantes, F | 1 |
| Martinez-Trillos, A | 1 |
| Adam, Z | 1 |
| Pour, L | 1 |
| Krejčí, M | 1 |
| Ševčíková, S | 1 |
| Pourová, E | 1 |
| Ševčíková, E | 1 |
| Král, Z | 1 |
| Mayer, J | 1 |
| Eve, HE | 1 |
| Rule, SA | 1 |
| Dasanu, CA | 1 |
| Schwartz, RA | 1 |
| Bauer, F | 1 |
| Davis, LK | 1 |
| Silver, JS | 1 |
| Reale, MA | 1 |
| Mesa, RA | 2 |
| Steensma, DP | 1 |
| Pardanani, A | 1 |
| Li, CY | 1 |
| Elliott, M | 2 |
| Kaufmann, SH | 1 |
| Wiseman, G | 1 |
| Gray, LA | 1 |
| Schroeder, G | 1 |
| Reeder, T | 1 |
| Zeldis, JB | 2 |
| Tefferi, A | 3 |
| Barosi, G | 2 |
| Giovanni, B | 1 |
| Michelle, E | 1 |
| Canepa, L | 1 |
| Letizia, C | 1 |
| Ballerini, F | 1 |
| Filippo, B | 1 |
| Piccaluga, PP | 1 |
| Pier Paolo, P | 1 |
| Visani, G | 1 |
| Giuseppe, V | 1 |
| Marchetti, M | 2 |
| Monia, M | 1 |
| Pozzato, G | 1 |
| Gabriele, P | 1 |
| Zorat, F | 1 |
| Francesca, Z | 1 |
| Ayalew, T | 1 |
| Balestri, F | 1 |
| Viarengo, G | 1 |
| Gentili, S | 1 |
| Barulli, S | 1 |
| Demory, JL | 1 |
| Ilariucci, F | 1 |
| Volpe, A | 1 |
| Bordessoule, D | 1 |
| Grossi, A | 1 |
| Le Bousse-Kerdiles, MC | 1 |
| Caenazzo, A | 1 |
| Pecci, A | 1 |
| Falcone, A | 1 |
| Broccia, G | 1 |
| Bendotti, C | 1 |
| Bauduer, F | 1 |
| Buccisano, F | 1 |
| Dupriez, B | 1 |
| Cortes, J | 1 |
| Verstovsek, S | 1 |
| Thomas, D | 1 |
| Lasho, TL | 1 |
| Hogan, WJ | 1 |
| Litzow, MR | 1 |
| Allred, JB | 1 |
| Jones, D | 1 |
| Byrne, C | 1 |
| Ketterling, RP | 1 |
| McClure, RF | 1 |
| Giles, F | 1 |
| Kantarjian, HM | 1 |
| Berrebi, A | 1 |
| Feldberg, E | 1 |
| Spivak, I | 1 |
| Shvidel, L | 1 |
| Field, EO | 1 |
| Gibbs, JE | 1 |
| Tucker, DF | 1 |
| Hellmann, K | 1 |
2 reviews available for thalidomide and Enlarged Spleen
| Article | Year |
|---|---|
Myelofibrosis: an update on current pharmacotherapy and future directions.
Topics: Age Factors; Androgens; Anemia; Humans; Immunologic Factors; Janus Kinase 2; Mutation; Nitriles; Pri | 2013 |
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc | 2016 |
4 trials available for thalidomide and Enlarged Spleen
| Article | Year |
|---|---|
Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.
Topics: Adult; Aged; Bone Marrow; Fatigue; Female; Fever; Gastrointestinal Diseases; Hematologic Diseases; H | 2013 |
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
Topics: Adrenal Cortex Hormones; Aged; Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Ant | 2003 |
Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Female; Humans; Immunosuppressive Agents; Leukop | 2004 |
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Topics: Administration, Oral; Adult; Aged; Anemia; Anemia, Myelophthisic; Female; Hemoglobins; Humans; Janus | 2006 |
6 other studies available for thalidomide and Enlarged Spleen
| Article | Year |
|---|---|
Case report of coexistence of myeloproliferative neoplasms and multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Bortezomib; Dexameth | 2020 |
Lenalidomide-induced tumour flare reaction in mantle cell lymphoma.
Topics: Antineoplastic Agents; Drug Eruptions; Fatal Outcome; Female; Humans; Lenalidomide; Leukocytosis; Ly | 2010 |
Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; D | 2011 |
Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Clinical Trials, Phase II as Topic; Female; Hemoglobins; Hum | 2002 |
Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Blood Transfusion; Bone Marrow; Combined Modality Therap | 2007 |
Effect of thalidomide on the graft versus host reaction.
Topics: Animals; Chick Embryo; Rats; Splenomegaly; Thalidomide; Transplantation Immunology | 1966 |